Stay updated on Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedA site-wide notice about funding-related delays was added, and the page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check11 days agoChange DetectedAdded a glossary toggle and updated footer/labels to reflect QC status and version (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). Removed older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page footer now shows Revision: v3.3.4, replacing the earlier Revision: v3.3.3. No study content, enrollment data, or results are affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check46 days agoChange DetectedAdded a comprehensive Locations section listing study sites by state (Alabama through Wisconsin) with revision tag v3.3.3.SummaryDifference1%

- Check75 days agoChange DetectedThe Publications section wording was updated to note that PubMed entries are automatically filled and may not all pertain to the study, and the Revision label was updated to v3.3.2.SummaryDifference0.0%

- Check82 days agoChange DetectedDeleted the general notice about a lapse in government funding and potential delays in updates. The study details and links on the page remain unchanged.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.